Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments
M. Nieto Barbero (Madrid, Spain), F. Gonzalez-Gamiz (Madrid, Spain), M. Rodríguez-Nieto (Madrid, Spain), S. Sanchez (Alcaá de Henares, Spain), J. Gaudo (Madrid, Spain), C. Valenzuela (Madrid, Spain), B. López-Muñíz (Madrid, Spain), L. Gomez-Carrera (Madrid, Spain), R. Laporta (Majadahonda, Spain), Á. Casanova (Coslada, Spain), M. Río (Getafe, Spain), R. Neumomadrid (Madrid, Spain)
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Session: Comorbidities of idiopathic pulmonary fibrosis
Session type: Thematic Poster
Number: 1301
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Nieto Barbero (Madrid, Spain), F. Gonzalez-Gamiz (Madrid, Spain), M. Rodríguez-Nieto (Madrid, Spain), S. Sanchez (Alcaá de Henares, Spain), J. Gaudo (Madrid, Spain), C. Valenzuela (Madrid, Spain), B. López-Muñíz (Madrid, Spain), L. Gomez-Carrera (Madrid, Spain), R. Laporta (Majadahonda, Spain), Á. Casanova (Coslada, Spain), M. Río (Getafe, Spain), R. Neumomadrid (Madrid, Spain). Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments. 1301
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: